The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Where did mm get those shares from?
Look at that late reported trade, humongous, never seen the like!
Morning El. Efficacy of Texrad continues through more evidence gathered and published in leading journal. We know we are on a journey but not sure of destination?
I believe there are legitimate grounds to report to FCA. Investors have made decisions on RNS and contact with company, if you look back at historical releases, they lack transparency, are clearly designed to show progress when there has been none. Specifically refer to JV with Future Processing and Texrad Lung JV with Allied Medical, long term holders will be very aware of these and commitments/milestones which have failed to materialize.
Thanks Bob. AGM on 23 January I think and would be prudent to give shareholders some decent update either before or on the day. Incredibly quiet with Investor Relations this lot. As for end of year price, haven't a clue!
Happy Christmas to one and all! In truth we are probably someway short of where we expected to be but not for the lack of superb support and research of a small band of long term holders. Special mention and thanks to Elartu, Botak and Bob. Have a wonderful Christmas with families and friends and most of all stay healthy and positive in 2019.
Hi mate. Totally agree with you on that, transparency isn't much in evidence! Cards being held very close....
Plenty of cash in bank £1.37m recent raise, lack of significant news and poor IR allied to poor markets generally and specifically AIM has contributed to drop. The shareholder contributors to equity raises in recent years amounts to nearly company value which values the products at nearly zero, absolutely ridiculous!
Thanks El, enjoyed the video and AR as usual a smooth presenter. It seems very positive and its first time he's mentioned II by name. He seems extremely confident about the future for the company with enough cash in bank to effect real progress. Looking forward to hearing next statements 're sales increasing. GO A
Company confirmed results out later today.
You honestly couldn't make it up! An infamous twitterati poster is ramping this on basis someone has bought 20% of company today. They haven't, it's a realignment of their % holding from 29% to 20% following admission of new shares. I do hold this stock but it's high risk and please don't get sucked in by idiots who have their own agenda. Having made that point it's very positive to see large volumes traded and no sell off by open offer placees who bought at 1.1p. The 20% holders also have warrants attached and you can bet they will be selling these at some stage. GLA.
Over 6% of company traded in first 2 hours of trading. Some will be placing flippers but at 16%+ some buyers are clearly interested at this level.
Hi Botak, results out before end of month, brace yourself mate!
You have great influence on the company mate, they appear to have deleted it! I saw it earlier and I concur.
IQAI, including Stonechecker, announced today first sale of software for clinical use in South Korea. We sold the rights to commercialize under licence for £50k, they have delivered product to market promptly and effectively in a very short timescale. We receive revenues under the licence, you have to be impressed and well done Balaji, Trevor and the rest of the team. I hold stock in both.
Meeting at 10am this morning to approve completion of placing. Expect company results and forward looking statements in next few days.
Hi Elartu. Surprised as you are mate! Sold two best players Maddison and Murphy for £37million to pay off debts, promoted unknown youngsters from Academy and suddenly all coming together. Oh, and signed a free transfer barrel chested centre forward from Finland called Temu Pukki who can't stop scoring! The QPR are on the up as well!! GLA.
Excellent Botak! When you put it like that...... Results out in next couple of weeks, placing to raise £1.37m completed in few days, announcement of Institutional Investor and forward looking statements with clinical usage, I think D.
Has been under estimated in this respect. The ability to record vast quantity of patient data and using Texrad to analyse and refine medical imaging software is a significant USP in our product portfolio. I expect to see many more sales of Cadran at £150,000 a go plus support revenues associated.
Just watched very interesting program on use of AI in healthcare. The early adopters who will succeed will have significant evidence based peer reviewed data which informs clinicians involved in healthcare. Feedback through Texrad provides dozens of examples from world leading research hospitals of evidence for oncolgy and other diseases which should place it at the forefront in the medical imaging field.